ZCCHC14 Knockout cell line (HT-29)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZCCHC14 (zinc finger CCHC-type containing 14) encodes a zinc finger-containing protein predicted to participate in nucleic acid- and phosphatidylinositol-binding processes. The protein is also predicted to bind zinc ions, consistent with a potential role in molecular interactions involving nucleic acids or cellular membranes. Its specific biological functions and regulatory pathways remain incompletely characterized, providing a basis for functional studies of this protein.

HT-29 is a human colorectal adenocarcinoma cell line established from a primary colon tumor of a 44-year-old female patient in 1964. The cells can undergo differentiation into mature goblet-like cells and produce mucin-secreting subclones, such as HT29-MTX, which exhibit characteristics of intestinal epithelial differentiation, including tight junction formation and mucus layer production. HT-29 is widely used as a model for studying colorectal cancer biology, intestinal epithelial differentiation, barrier function, and drug or nanoparticle transport.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.